CN117545739A - 新型n,n-二甲基色胺盐和结晶盐形式 - Google Patents

新型n,n-二甲基色胺盐和结晶盐形式 Download PDF

Info

Publication number
CN117545739A
CN117545739A CN202280037486.9A CN202280037486A CN117545739A CN 117545739 A CN117545739 A CN 117545739A CN 202280037486 A CN202280037486 A CN 202280037486A CN 117545739 A CN117545739 A CN 117545739A
Authority
CN
China
Prior art keywords
dmt
crystalline form
salt
succinate
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037486.9A
Other languages
English (en)
Chinese (zh)
Inventor
马吉德·法瓦兹
塞图·卡塞拉
尼古拉斯·莫拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Treatment Co
Original Assignee
Atai Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Treatment Co filed Critical Atai Treatment Co
Publication of CN117545739A publication Critical patent/CN117545739A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280037486.9A 2021-05-25 2022-05-25 新型n,n-二甲基色胺盐和结晶盐形式 Pending CN117545739A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192938P 2021-05-25 2021-05-25
US63/192,938 2021-05-25
PCT/US2022/030912 WO2022251351A1 (en) 2021-05-25 2022-05-25 New n,n-dimethyltryptamine salts and crystalline salt forms

Publications (1)

Publication Number Publication Date
CN117545739A true CN117545739A (zh) 2024-02-09

Family

ID=84230260

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037486.9A Pending CN117545739A (zh) 2021-05-25 2022-05-25 新型n,n-二甲基色胺盐和结晶盐形式

Country Status (12)

Country Link
US (3) US12378194B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347562A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521747A (cg-RX-API-DMAC7.html)
KR (1) KR20240013170A (cg-RX-API-DMAC7.html)
CN (1) CN117545739A (cg-RX-API-DMAC7.html)
AU (1) AU2022281358A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024550A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218110A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003518A1 (cg-RX-API-DMAC7.html)
IL (1) IL308816A (cg-RX-API-DMAC7.html)
MX (1) MX2023013928A (cg-RX-API-DMAC7.html)
WO (1) WO2022251351A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117320711A (zh) * 2021-04-26 2023-12-29 阿泰治疗公司 新型n,n-二甲基色胺组合物和方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2022251169A1 (en) 2021-05-24 2022-12-01 Canna-Chemistries Llc Crystalline salts of psilocin
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
AU2023313326A1 (en) * 2022-07-27 2024-12-19 Reconnect Labs Ag Highly soluble formulations of harmine

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2102303A1 (en) 1991-06-19 1992-12-20 Roy Allen Johnson Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
JP3361836B2 (ja) 1991-07-04 2003-01-07 三共株式会社 アミノ酸誘導体
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
US6025374A (en) 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
US6500456B1 (en) 1997-10-03 2002-12-31 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
US6488648B1 (en) 1999-01-14 2002-12-03 Teijin Limited Device for feeding a powder in a predetermined amount and method thereof
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
HUP0202143A3 (en) 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20050245594A1 (en) 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
AU2002340083A1 (en) 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
AU2005244770A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7429575B2 (en) 2006-01-10 2008-09-30 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
CA2642685A1 (en) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
HRP20120479T1 (hr) 2006-06-28 2012-07-31 Chelsea@Therapeutics@Inc Farmaceutski sastavi sa droksidopom
US20080227830A1 (en) * 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
CA2686994A1 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
JP5620907B2 (ja) * 2008-06-19 2014-11-05 エルテーエスローマン テラピー−ジステーメ アーゲー カチオン性活性剤の経皮送達のための組成物
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
WO2011041870A1 (en) 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
JP2014189462A (ja) * 2013-03-27 2014-10-06 Osaka Univ 結晶製造方法、準安定形結晶、医薬の製造方法および医薬
EP2796139A1 (en) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
EP3110419A4 (en) 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
WO2018094005A1 (en) 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
JP2021514682A (ja) 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー トリプタミンの生産方法
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
EP3841085B1 (en) 2018-08-22 2026-05-06 University Of Technology Sydney Nbome test
DK3927338T3 (da) 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
US20210236523A1 (en) 2020-02-05 2021-08-05 Yale University Psychedelic treatment for headache disorders
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
WO2021226041A1 (en) 2020-05-04 2021-11-11 Caamtech, Inc. Crystalline dimethyl tryptamine analogues
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
EP4208457A1 (en) 2020-09-04 2023-07-12 Gilgamesh Pharmaceuticals, Inc. Azetidinyl tryptamines and methods of treating psychiatric disorders
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
WO2022082058A1 (en) 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
WO2022123232A1 (en) 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
EP4274831A4 (en) 2021-01-11 2024-05-01 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses
WO2022160056A1 (en) 2021-01-29 2022-08-04 Algernon Pharmaceuticals Inc. Dmt salts and their use to treat brain injury
US20240189331A1 (en) 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3216889A1 (en) 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
EP4333979A4 (en) 2021-05-03 2025-01-15 Mind Medicine, Inc. Method of titrating dose of psychedelics
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
WO2022246572A1 (en) 2021-05-26 2022-12-01 Mindset Pharma Inc. Hallucinogen-fatty acid combination
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
WO2023283386A2 (en) 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
EP4137131A1 (en) 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
AU2022342266B2 (en) 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies
US20230310374A1 (en) 2021-09-30 2023-10-05 ATAI Life Sciences AG Compositions and methods for treating headache or facial pain
EP4408412A4 (en) 2021-09-30 2025-07-16 ATAI Life Sciences AG COMPOSITIONS AND METHODS FOR TREATING HEADACHES
AU2022413759A1 (en) 2021-12-13 2024-06-27 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4584247A2 (en) 2022-09-06 2025-07-16 ATAI Therapeutics, Inc. Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
EP4608395A2 (en) 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
WO2024118767A2 (en) 2022-11-29 2024-06-06 Caamtech, Inc. Tryptamine derivatives
TW202430149A (zh) 2022-12-01 2024-08-01 美商雅特益醫療公司 N,n-二甲基色胺之結晶形式及其使用方法
EP4633625A2 (en) 2022-12-15 2025-10-22 ATAI Therapeutics, Inc. Prodrugs of dimethyltryptamine and derivatives thereof
EP4704833A2 (en) 2023-04-27 2026-03-11 ATAI Therapeutics, Inc. Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117320711A (zh) * 2021-04-26 2023-12-29 阿泰治疗公司 新型n,n-二甲基色胺组合物和方法

Also Published As

Publication number Publication date
MX2023013928A (es) 2023-12-08
CA3218110A1 (en) 2022-12-01
JP2024521747A (ja) 2024-06-04
BR112023024550A2 (pt) 2024-02-06
EP4347562A1 (en) 2024-04-10
WO2022251351A4 (en) 2022-12-29
WO2022251351A1 (en) 2022-12-01
CL2023003518A1 (es) 2024-05-03
US20260116853A1 (en) 2026-04-30
KR20240013170A (ko) 2024-01-30
EP4347562A4 (en) 2025-04-30
AU2022281358A1 (en) 2023-11-23
US20250388538A1 (en) 2025-12-25
IL308816A (en) 2024-01-01
US12378194B2 (en) 2025-08-05
US20220388956A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US12378194B2 (en) N, n-dimethyltryptamine salts and crystalline salt forms
CN117320711A (zh) 新型n,n-二甲基色胺组合物和方法
TWI727949B (zh) 調節蛋白質激酶之化合物的固態形式
RU2468797C2 (ru) Способ и композиция для лечения воспалительных нарушений
JP5502494B2 (ja) メタニコチンアナログの鼻腔内、バッカル、または舌下投与
KR20130135296A (ko) 베포타스틴 조성물
CA3047428A1 (en) Pharmaceutical dosage forms comprising inhibitors of task-1 and task-3 channels and use thereof for therapy of respiratory disorders
US20200093737A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
US11814383B2 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CA3130619C (en) Naloxone formulations for sublingual and/or buccal administration
JP2025502208A (ja) トリプタミン組成物および方法
JP2008512429A (ja) ロフルミラストとsykインヒビターとの組合せ物並びにその使用方法
US12171758B1 (en) Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
JP2022504410A (ja) パーキンソン病の処置のための組成物及び方法
CN120112511A (zh) 苯乙胺化合物、组合物和使用方法
KR20240168342A (ko) 흡입에 의한 정신자극제 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템
CN111655666A (zh) 抗炎、抗癌和抗血管生成化合物,药物组合物及其制备和使用方法
US20110190332A1 (en) Dopamine receptor ligands with enhanced duration of action
HK40105474A (en) Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceuticals compositions, and methods of making and using thereof
TW200900401A (en) Novel salt
HK40010023A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
EP3338803A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
WO2005102344A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination